154 related articles for article (PubMed ID: 38730739)
1. Expression of Potential Antibody-Drug Conjugate Targets in Cervical Cancer.
Mallmann MR; Tamir S; Alfter K; Ratiu D; Quaas A; Domroese CM
Cancers (Basel); 2024 May; 16(9):. PubMed ID: 38730739
[TBL] [Abstract][Full Text] [Related]
2. Assessment of TROP2, CEACAM5 and DLL3 in metastatic prostate cancer: Expression landscape and molecular correlates.
Ajkunic A; Sayar E; Roudier MP; Patel RA; Coleman IM; De Sarkar N; Hanratty B; Adil M; Zhao J; Zaidi S; True LD; Sperger JM; Cheng HH; Yu EY; Montgomery RB; Hawley JE; Ha G; Persse T; Galipeau P; Lee JK; Harmon SA; Corey E; Lang JM; Sawyers CL; Morrissey C; Schweizer MT; Gulati R; Nelson PS; Haffner MC
NPJ Precis Oncol; 2024 May; 8(1):104. PubMed ID: 38760413
[TBL] [Abstract][Full Text] [Related]
3. ASSESSMENT OF CELL SURFACE TARGETS IN METASTATIC PROSTATE CANCER: EXPRESSION LANDSCAPE AND MOLECULAR CORRELATES.
Ajkunic A; Sayar E; Roudier MP; Patel RA; Coleman IM; De Sarkar N; Hanratty B; Adil M; Zhao J; Zaidi S; True LD; Sperger JM; Cheng HH; Yu EY; Montgomery RB; Hawley JE; Ha G; Lee JK; Harmon SA; Corey E; Lang JM; Sawyers CL; Morrissey C; Schweizer MT; Gulati R; Nelson PS; Haffner MC
Res Sq; 2023 Dec; ():. PubMed ID: 38196594
[TBL] [Abstract][Full Text] [Related]
4. Unlocking New Horizons in Small-Cell Lung Cancer Treatment: The Onset of Antibody-Drug Conjugates.
Belluomini L; Sposito M; Avancini A; Insolda J; Milella M; Rossi A; Pilotto S
Cancers (Basel); 2023 Nov; 15(22):. PubMed ID: 38001628
[TBL] [Abstract][Full Text] [Related]
5. Antibody-drug conjugates: A promising novel therapeutic approach in lung cancer.
Desai A; Abdayem P; Adjei AA; Planchard D
Lung Cancer; 2022 Jan; 163():96-106. PubMed ID: 34942494
[TBL] [Abstract][Full Text] [Related]
6. Antibody Drug Conjugates in Lung Cancer.
Merle G; Friedlaender A; Desai A; Addeo A
Cancer J; 2022 Nov-Dec 01; 28(6):429-435. PubMed ID: 36383905
[TBL] [Abstract][Full Text] [Related]
7. Chimeric antigen receptor-T cells are effective against CEACAM5 expressing non-small cell lung cancer cells resistant to antibody-drug conjugates.
Kim YJ; Li W; Zhelev DV; Mellors JW; Dimitrov DS; Baek DS
Front Oncol; 2023; 13():1124039. PubMed ID: 36923424
[TBL] [Abstract][Full Text] [Related]
8. The target invites a foe: antibody-drug conjugates in gynecologic oncology.
Campos MP; Konecny GE
Curr Opin Obstet Gynecol; 2018 Feb; 30(1):44-50. PubMed ID: 29227302
[TBL] [Abstract][Full Text] [Related]
9. Leveraging TROP2 Antibody-Drug Conjugates in Solid Tumors.
Nelson BE; Meric-Bernstam F
Annu Rev Med; 2024 Jan; 75():31-48. PubMed ID: 37758237
[TBL] [Abstract][Full Text] [Related]
10. Antibody-Drug Conjugates in Non-Small Cell Lung Cancer: Emergence of a Novel Therapeutic Class.
Marks JA; Wilgucki M; Liu SV; Reuss JE
Curr Oncol Rep; 2022 Dec; 24(12):1829-1841. PubMed ID: 36197593
[TBL] [Abstract][Full Text] [Related]
11. TROP2 as Patient-Tailoring but Not Prognostic Biomarker for Breast Cancer.
Liu X; Zhou T; Wang Y; Pei M; Wang G; Chu W; Wang Q; Du S; Wang H; Wang C
Onco Targets Ther; 2022; 15():509-520. PubMed ID: 35535168
[TBL] [Abstract][Full Text] [Related]
12. Next-generation antibody-drug conjugates for breast cancer: Moving beyond HER2 and TROP2.
Schlam I; Moges R; Morganti S; Tolaney SM; Tarantino P
Crit Rev Oncol Hematol; 2023 Oct; 190():104090. PubMed ID: 37562695
[TBL] [Abstract][Full Text] [Related]
13. A literature review of the promising future of
Wen Y; Ouyang D; Zou Q; Chen Q; Luo N; He H; Anwar M; Yi W
Ann Transl Med; 2022 Dec; 10(24):1403. PubMed ID: 36660684
[TBL] [Abstract][Full Text] [Related]
14. CT109-SN-38, a Novel Antibody-drug Conjugate with Dual Specificity for CEACAM5 and 6, Elicits Potent Killing of Pancreatic Cancer Cells.
Arias Cardenas KC; Enos CW; Spear MR; Austin DE; Almofeez R; Kortchak S; Pincus L; Guo HB; Dolezal S; Pierce JM; Furth E; Gineste C; Kwon Y; Gelber C
Curr Cancer Drug Targets; 2024 Jan; ():. PubMed ID: 38178674
[TBL] [Abstract][Full Text] [Related]
15. Epigenetically upregulating TROP2 and SLFN11 enhances therapeutic efficacy of TROP2 antibody drug conjugate sacitizumab govitecan.
Zhao M; DiPeri TP; Raso MG; Zheng X; Rizvi YQ; Evans KW; Yang F; Akcakanat A; Roberto Estecio M; Tripathy D; Dumbrava EE; Damodaran S; Meric-Bernstam F
NPJ Breast Cancer; 2023 Aug; 9(1):66. PubMed ID: 37567892
[TBL] [Abstract][Full Text] [Related]
16. Antibody drug conjugates in non-small cell lung cancer: An emerging therapeutic approach.
Marks S; Naidoo J
Lung Cancer; 2022 Jan; 163():59-68. PubMed ID: 34923203
[TBL] [Abstract][Full Text] [Related]
17. Integrating antibody drug conjugates in the management of gynecologic cancers.
Chelariu-Raicu A; Mahner S; Moore KN; Lorusso D; Coleman RL
Int J Gynecol Cancer; 2023 Mar; 33(3):420-429. PubMed ID: 36878560
[TBL] [Abstract][Full Text] [Related]
18. High levels of expression of Trop-2 in thymic epithelial tumors.
Yeung V; Zaemes J; Yeh J; Giancarlo C; Ahn J; Reuss JE; Kallakury BV; Liu SV; Duttargi A; Khan G; Kim C
Lung Cancer; 2023 Oct; 184():107324. PubMed ID: 37573703
[TBL] [Abstract][Full Text] [Related]
19. Data-Driven prioritisation of antibody-drug conjugate targets in head and neck squamous cell carcinoma.
Hanemaaijer SH; van Gijn SE; Oosting SF; Plaat BEC; Moek KL; Schuuring EM; van der Laan BFAM; Roodenburg JLN; van Vugt MATM; van der Vegt B; Fehrmann RSN
Oral Oncol; 2018 May; 80():33-39. PubMed ID: 29706186
[TBL] [Abstract][Full Text] [Related]
20. Shedding light on triple-negative breast cancer with Trop2-targeted antibody-drug conjugates.
Jabbarzadeh Kaboli P; Shabani S; Sharma S; Partovi Nasr M; Yamaguchi H; Hung MC
Am J Cancer Res; 2022; 12(4):1671-1685. PubMed ID: 35530278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
